PerSort facilitates characterization and elimination of persister subpopulation in mycobacteria
V. Srinivas, M. L. Arrieta-Ortiz, E. J. R. Peterson, N. S. Baliga
Abstract
Mycobacterium tuberculosis (MTB) generates phenotypic diversity to persist and survive the harsh conditions encountered during infection. MTB avoids immune effectors and antibacterial killing by entering into distinct physiological states. The surviving cells, persisters, are a major barrier to the timely and relapse-free treatment of tuberculosis (TB). We present for the first time, PerSort, a method to isolate and characterize persisters in the absence of antibiotic, or other pressure. We demonstrate the value of PerSort to isolate translationally dormant cells that pre-exist in small numbers within Mycobacterium spp. cultures growing under optimal conditions, but which dramatically increased in proportion under stress conditions. The translationally dormant subpopulation exhibited multidrug tolerance and regrowth properties consistent with persister cells. Furthermore, PerSort enabled single-cell transcriptional profiling that provided evidence that the translationally dormant persisters were generated through a variety of mechanisms, including vapC30, mazF, and relA/spoT overexpression. Finally, we demonstrate that notwithstanding the varied mechanisms by which the persister cells were generated, they converge on a similar low oxygen metabolic state that was reversed through activation of respiration to rapidly eliminate persisters fostered under host-relevant stress conditions. We conclude that PerSort provides a new tool to study MTB persisters, enabling targeted strategies to improve and shorten the treatment of TB. SummaryWe have developed a novel method, PerSort, to isolate translationally dormant cells that pre-exist in small numbers within Mycobacterium spp. cultures growing under naive conditions (i.e., absence of antibiotic treatment), but dramatically increase in proportion under stress conditions. The translationally dormant cells have high tolerance to isoniazid and rifampicin, and can regenerate the parental population structure in standard media, albeit after a significantly longer lag phase, indicating they are persister cells. Single-cell expression profiling demonstrated that the translationally dormant persister subpopulation is a mixture of vapC30, mazF, and relA/spoT overexpressing cells, indicating there are multiple pathways to become a persister cell. Regardless of the mechanism by which they are generated, the persister cells have reduced oxidative metabolism, which is reversed upon addition of L-cysteine to effect complete clearance by INH and RIF under host-related stress.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Noise in a metabolic pathway leads to persister formation in Mycobacterium tuberculosis
J. Quigley, K. Lewis·Microbiology SpectrumPeer-reviewed·Oct 26, 2022
- A new Persister Enrichment Model in Mycobacterium tuberculosis links multidrug persistence to drug sequencing and maltokinase-dependent carbon distribution.
Michael W. Shultis, Claire V. Mulholland, … Michael Berney·bioRxiv·May 29, 2026
- Host cholesterol dependent activation of VapC12 toxin enriches persister population during Mycobacterium tuberculosis infection
A. K. Pandey, S. Talwar, … A. Singhal·bioRxiv·Nov 26, 2019
- Adaptation of Mycobacterium tuberculosis to biofilm growth is genetically linked to drug tolerance
J. P. Richards, W. Cai, … A. K. Ojha·bioRxiv·Jun 6, 2019
- Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice
Elizabeth A. Wynn, Christian Dide-Agossou, … Nicholas D. Walter·Antimicrobial Agents and ChemotherapyPeer-reviewed·Jan 17, 2025
- Netupitant Exhibits Potent Activity on Mycobacterium tuberculosis Persisters
Hassan E. Eldesouky, Richard M. Jones, … David R. Sherman·ACS Infectious DiseasesPeer-reviewed·Jul 18, 2025